Gina Scurti

776 total citations
23 papers, 539 citations indexed

About

Gina Scurti is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Gina Scurti has authored 23 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in Gina Scurti's work include CAR-T cell therapy research (16 papers), Immunotherapy and Immune Responses (7 papers) and Immune Cell Function and Interaction (6 papers). Gina Scurti is often cited by papers focused on CAR-T cell therapy research (16 papers), Immunotherapy and Immune Responses (7 papers) and Immune Cell Function and Interaction (6 papers). Gina Scurti collaborates with scholars based in United States, Egypt and Sweden. Gina Scurti's co-authors include Michael I. Nishimura, Elizabeth Garrett‐Mayer, Shikhar Mehrotra, Patricia Simms, Christina Voelkel‐Johnson, Chrystal M. Paulos, Mohamed L. Salem, Mark P. Rubinstein, Mingli Li and David J. Cole and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Gina Scurti

23 papers receiving 535 citations

Peers

Countries citing papers authored by Gina Scurti

Since Specialization

Citations

This map shows the geographic impact of Gina Scurti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gina Scurti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gina Scurti more than expected).

Fields of papers citing papers by Gina Scurti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gina Scurti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gina Scurti. The network helps show where Gina Scurti may publish in the future.

Co-authorship network of co-authors of Gina Scurti

This figure shows the co-authorship network connecting the top 25 collaborators of Gina Scurti. A scholar is included among the top collaborators of Gina Scurti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gina Scurti. Gina Scurti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus 2024 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), Elena Cherkasova, Timothy T. Spear, (unknown), (unknown), Gina Scurti, Long Chen, (unknown), (unknown), Gang Zeng, Gordon Parry, David F. Stroncek, Steven L. Highfill, (unknown), Robert Reger, Michael I. Nishimura, Richard Childs	5
2	T cell receptor-engineered T cells targeting a human endogenous retrovirus in kidney cancer. 2023 ·Journal of Clinical Oncology ·(unknown), (unknown), Elena Cherkasova, Rosa Nadal, (unknown), (unknown), Long Chen, Timothy T. Spear, Gina Scurti, Gang Zeng, Gordon Parry, David F. Stroncek, Steven L. Highfill, (unknown), Robert Reger, Michael I. Nishimura, Richard Childs	2
3	Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior 2023 ·Blood Advances ·Siao‐Yi Wang, Gina Scurti, (unknown), (unknown), Patrick J. Stiff, Michael I. Nishimura	8
4	Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC). 2023 ·Journal of Clinical Oncology ·Rosa Nadal, (unknown), Gina Scurti, Elena Cherkasova, Long Chen, (unknown), Steven L. Highfill, (unknown), Georg Aue, (unknown), Thomas E. Hughes, Xin Tian, Yifei Xu, Ashkan A. Malayeri, Mohammadhadi Bagheri, Robert Reger, Michael I. Nishimura, Richard Childs	4
5	Siglec‐5 is an inhibitory immune checkpoint molecule for human T cells 2022 ·Immunology ·(unknown), (unknown), Gina Scurti, Michael I. Nishimura, Paula White, Andrew T. Ulijasz, Makio Iwashima	45
6	Transdifferentiation of high-grade B-cell lymphoma with MYC and BCL2 rearrangements into histiocytic sarcoma after CAR T-cell therapy: a case report 2022 ·Journal of Hematopathology ·(unknown), Amanda J. Nguyen, (unknown), Gina Scurti, (unknown), (unknown), (unknown), (unknown), Rhett P. Ketterling, Michael I. Nishimura, (unknown), Nasheed Hossain	1
7	Genetic Modification of T Cells for the Immunotherapy of Cancer 2022 ·Vaccines ·(unknown), (unknown), (unknown), Gina Scurti, Nasheed Hossain, Michael I. Nishimura	6
8	HDAC inhibition prevents transgene expression downregulation and loss-of-function in T cell-receptor-transduced T cells 2021 ·Molecular Therapy — Oncolytics ·Tamson V. Moore, Gina Scurti, (unknown), Siao‐Yi Wang, (unknown), (unknown), (unknown), Jodi Speiser, Constantine Godellas, (unknown), (unknown), Tarsem Moudgil, (unknown), David J. Murray, Brendan D. Curti, Joseph I. Clark, Bernard A. Fox, Michael I. Nishimura	7
9	Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response 2021 ·Scientific Reports ·Siao‐Yi Wang, Tamson V. Moore, (unknown), Gina Scurti, Michael I. Nishimura	7
10	N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner 2018 ·Cancer Immunology Immunotherapy ·(unknown), Gina Scurti, Megan M. Wyatt, Elizabeth Garrett‐Mayer, Chrystal M. Paulos, Michael I. Nishimura, Christina Voelkel‐Johnson	38
11	Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells 2017 ·Cancer Immunology Immunotherapy ·Timothy T. Spear, Yuan Wang, (unknown), David C. Murray, Gina Scurti, Patricia Simms, Elizabeth Garrett‐Mayer, Lance M. Hellman, Brian M. Baker, Michael I. Nishimura	15
12	Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer 2017 ·Journal of Hematology & Oncology ·Shikhar Mehrotra, Carolyn D. Britten, Steve Chin, Elizabeth Garrett‐Mayer, (unknown), Mingli Li, Gina Scurti, Mohamed L. Salem, Michelle H. Nelson, Melanie B. Thomas, Chrystal M. Paulos, Andres Μ. Salazar, Michael I. Nishimura, Mark P. Rubinstein, Zihai Li, David J. Cole	121
13	Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists 2017 ·Cancer Immunology Immunotherapy ·Tanja Lövgren, Dhifaf Sarhan, Iva Truxová, (unknown), Roeltje R. Maas, Jeroen Melief, Maria Nyström, (unknown), Renee Vermeij, Gina Scurti, Michael I. Nishimura, Giuseppe Masucci, Alex Karlsson‐Parra, Andreas Lundqvist, Lars Adamson, Rolf Kiessling	30
14	Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death 2016 ·Cancer Research ·(unknown), Gina Scurti, Patricia Simms, Elizabeth Garrett‐Mayer, Shikhar Mehrotra, Michael I. Nishimura, Christina Voelkel‐Johnson	58
15	TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors 2016 ·Cancer Immunology Immunotherapy ·Timothy T. Spear, Glenda G. Callender, J. Roszkowski, (unknown), Patricia Simms, (unknown), David C. Murray, Gina Scurti, Mingli Li, (unknown), Alexander Langerman, Elizabeth Garrett‐Mayer, Yi Zhang, Michael I. Nishimura	45
16	Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability 2016 ·Journal of Leukocyte Biology ·Timothy T. Spear, Timothy P. Riley, Gretchen E. Lyons, Glenda G. Callender, J. Roszkowski, Yuan Wang, Patricia Simms, Gina Scurti, (unknown), David C. Murray, Lance M. Hellman, Rachel H. McMahan, Makio Iwashima, Elizabeth Garrett‐Mayer, Hugo R. Rosen, Brian M. Baker, Michael I. Nishimura	16
17	FAK Mediates a Compensatory Survival Signal Parallel to PI3K-AKT in PTEN-Null T-ALL Cells 2015 ·Cell Reports ·Dewen You, Junping Xin, Andrew Volk, Wei Wei, (unknown), Gina Scurti, Sucha Nand, Eun‐Kyoung Breuer, Paul C. Kuo, Peter Breslin, Ameet R. Kini, Michael I. Nishimura, Nancy J. Zeleznik‐Le, Jiwang Zhang	41
18	Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8+ T cells 2015 ·Cancer Immunology Immunotherapy ·Mark P. Rubinstein, Ee Wern Su, Samantha Suriano, (unknown), (unknown), Pravin Kesarwani, (unknown), Katelyn Williams, Christopher Johnson, Mingli Li, Gina Scurti, Mohamed L. Salem, Chrystal M. Paulos, Elizabeth Garrett‐Mayer, Shikhar Mehrotra, David J. Cole	32
19	T-cell therapy in metastatic melanoma: TIL 1383I TCR transduced T cells after infusion and activity in vivo. 2015 ·Journal of Clinical Oncology ·(unknown), Joseph I. Clark, Tamson V. Moore, (unknown), Gina Scurti, Ann L. Clark, Boro Dropulić, Heather Embree, Keisuke Shirai, Elizabeth Garrett‐Mayer, Mingli Li, (unknown), Jonathan M. Eby, Caroline Le Poole, Michael I. Nishimura	1
20	Promoting Thiol Expression Increases the Durability of Antitumor T-cell Functions 2014 ·Cancer Research ·Pravin Kesarwani, Amir A. Al-Khami, Gina Scurti, (unknown), (unknown), Shahid Husain, Quan Fang, Osama Naga, Patricia Simms, Gyda Beeson, Christina Voelkel‐Johnson, Elizabeth Garrett‐Mayer, Craig C. Beeson, Michael I. Nishimura, Shikhar Mehrotra	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact